东吴证券晨会纪要-20251113

Group 1: Macro Strategy - The current A-share market resembles the early stages of the 2020-2021 bull market, indicating a slow bull phase driven by strategic funds, similar to the role of foreign capital in early 2020 [1][8] - The market is expected to follow a structural "innovation bull" trend in 2026, as new funds and improved performance from domestic institutions emerge [1][8] Group 2: Fixed Income Market - The bond market remains in a box range, with the central bank maintaining liquidity through reverse repos and net purchases of government bonds, while new redemption fee regulations may cause volatility [2][9] - The 10-year government bond yield is expected to continue a narrow fluctuation pattern, with potential opportunities arising from rapid interest rate increases due to new redemption fee regulations [2][9] Group 3: Company Analysis - Fuxiang Pharmaceutical - Fuxiang Pharmaceutical is set to benefit from a significant increase in the price of vinyl carbonate (VC), which has risen 63% from 4.75 million CNY/ton to 7.75 million CNY/ton due to increased demand in the energy storage sector [6][20] - The company has invested in projects to produce 6,000 tons of lithium battery additives annually, positioning itself as a leader in the industry [6][20] - The decline in the price of 6-APA, a key raw material, is expected to enhance the company's gross margin as high-cost inventory is consumed [6][20] Group 4: Company Analysis - Xiaogoods City - Xiaogoods City has acquired land to develop an integrated cultural and commercial complex, which is expected to expand its market presence and increase revenue and profit [7] - The projected net profit for 2025-2027 is 49.0 billion CNY, 61.6 billion CNY, and 72.8 billion CNY, reflecting growth rates of 59%, 26%, and 18% respectively [7]